
OncoTargets and Therapy p. 5077 - 5087 (2017)
Update date:2022-09-26
Topics:
Zhou, Yan
Zhang, Genyan
Wang, Feng
Wang, Jin
Ding, Yanwei
Li, Xinyu
Shi, Chongtie
Li, Jiakui
Shih, Chengkon
You, Song
This study presents a process of developing a novel PI3K-mTOR inhibitor through the prodrug of a metabolite. The lead compound (compound 1) was identified with similar efficacy as that of NVP-BEZ235 in a tumor xenograft model, but the exposure of compound
View MoreBeijing Zhongshuo Pharmaceutical T & D Co.,Ltd
Contact:0086-10-64430626
Address:ea No 16, HEPINGLI,DONGCHENG DISTRICT,BEIJING,P.R.CHINA.
Shijiazhuang Sdyano Fine Chemical Co., Ltd
Contact:+86-311-89830448
Address:NO.48 Ta Nan Road,Yuhua District,Shijiazhuang,Hebei,China
Jinhua Haoyuan Chemical CO., LTD(expird)
Contact:86-579-82465583
Address:Jinhua,Zhejiang
Nantong LiKai Chemical Co.,Ltd
Contact:+86-513-89068669
Address:Jincheng Science Park
Contact:86-10-62983737; +86-10-51287608
Address:4/F Building C, 2 Shangdi Xinxi Road
Doi:10.1016/j.tet.2012.10.103
(2013)Doi:10.1002/adsc.201200925
(2013)Doi:10.1016/j.bmcl.2012.11.098
(2013)Doi:10.1021/jo302487c
(2013)Doi:10.1016/S0040-4020(01)00787-6
(2001)Doi:10.1002/hlca.201200557
(2012)